Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Pyruvate metabolism dictates fibroblast sensitivity to GLS1 inhibition during fibrogenesis
Greg Contento, Jo-Anne A.M. Wilson, Brintha Selvarajah, Manuela Platé, Delphine Guillotin, Valle Morales, Marcello Trevisani, Vanessa Pitozzi, Katiuscia Bianchi, Rachel C. Chambers
Greg Contento, Jo-Anne A.M. Wilson, Brintha Selvarajah, Manuela Platé, Delphine Guillotin, Valle Morales, Marcello Trevisani, Vanessa Pitozzi, Katiuscia Bianchi, Rachel C. Chambers
View: Text | PDF
Research Article Cell biology Metabolism

Pyruvate metabolism dictates fibroblast sensitivity to GLS1 inhibition during fibrogenesis

  • Text
  • PDF
Abstract

Fibrosis is a chronic disease characterized by excessive extracellular matrix production, which leads to disruption of organ function. Fibroblasts are key effector cells of this process, responding chiefly to the pleiotropic cytokine transforming growth factor–β1 (TGF-β1), which promotes fibroblast to myofibroblast differentiation. We found that extracellular nutrient availability profoundly influenced the TGF-β1 transcriptome of primary human lung fibroblasts and that biosynthesis of amino acids emerged as a top enriched TGF-β1 transcriptional module. We subsequently uncovered a key role for pyruvate in influencing glutaminase (GLS1) inhibition during TGF-β1–induced fibrogenesis. In pyruvate-replete conditions, GLS1 inhibition was ineffective in blocking TGF-β1–induced fibrogenesis, as pyruvate can be used as the substrate for glutamate and alanine production via glutamate dehydrogenase (GDH) and glutamic-pyruvic transaminase 2 (GPT2), respectively. We further show that dual targeting of either GPT2 or GDH in combination with GLS1 inhibition was required to fully block TGF-β1–induced collagen synthesis. These findings embolden a therapeutic strategy aimed at additional targeting of mitochondrial pyruvate metabolism in the presence of a glutaminolysis inhibitor to interfere with the pathological deposition of collagen in the setting of pulmonary fibrosis and potentially other fibrotic conditions.

Authors

Greg Contento, Jo-Anne A.M. Wilson, Brintha Selvarajah, Manuela Platé, Delphine Guillotin, Valle Morales, Marcello Trevisani, Vanessa Pitozzi, Katiuscia Bianchi, Rachel C. Chambers

×

Figure 5

Pyruvate confers resistance to GLS1 inhibition through GDH-driven glutamate and GPT2-driven alanine biosynthesis.

Options: View larger image (or click on image) Download as PowerPoint
Pyruvate confers resistance to GLS1 inhibition through GDH-driven glutam...
(A) Intracellular amino acid levels of pHLFs supplemented with dimethyl-α-ketoglutarate (4 mM) with 1 μM CB-839 and TGF-β1 (1 ng/mL) for 48 hours. (B) pHLFs were supplemented with dimethyl-α-ketoglutarate (4 mM) or pyruvate (1 mM) and preincubated with 1 μM CB-839 or 50 μM EGCG before stimulation with TGF-β1 (1 ng/mL) for 48 hours, and collagen I deposition was assessed by macromolecular crowding assay. (C) pHLFs were preincubated with increasing concentrations of EGCG for 1 hour before being stimulated with TGF-β1 (1 ng/mL) for 48 hours, and collagen I deposition was assessed by macromolecular crowding assay. (D) pHLFs were transfected with nontargeting (NT) siRNA or siRNA targeting GDH, cells were preincubated with 1 μM CB-839 and dimethyl-α-ketoglutarate (4 mM) before stimulation with TGF-β1 (1 ng/mL), and intracellular glutamate levels were quantified by HPLC after 48 hours. (E and F) pHLFs were treated with 1 μM CB-839 for 1 hour prior to TGF-β1 (1 ng/mL) stimulation for 24 hours, and RNA was quantified using quantitative PCR. (G) Immunoblot from pHLFs 24 hours following TGF-β1 stimulation (1 ng/mL) and 1 μM CB-839. (H) pHLFs were treated with 1 μM CB-839 for 1 hour supplemented with alanine or proline (500 μM) prior to TGF-β1 (1 ng/mL) stimulation for 48 hours, and collagen I deposition was assessed by macromolecular crowding assay. (I) pHLFs were supplemented with alanine (500 μM) before stimulation with TGF-β1 (1 ng/mL) and CB-839 (1 μM) for 48 hours, with intracellular proline measured by HPLC (n = 3). (J) pHLFs were treated as in B with alanine (500 μM) or pyruvate (1 mM) supplementation prior to a 1-hour preincubation with 20 μM l-cycloserine or 50 μM EGCG before stimulation with TGF-β1 (1 ng/mL) for 48 hours, and collagen I deposition was assessed by macromolecular crowding assay. (K) Schematic showing pyruvate and glutamine routing into the TCA cycle. Data are presented as mean ± SD, and differences were evaluated between groups with 2-way ANOVA with Tukey’s multiple-comparison testing.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts